Revolution Medicines (NASDAQ:RVMD – Get Free Report) and Cocrystal Pharma (NASDAQ:COCP – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.
Earnings and Valuation
This table compares Revolution Medicines and Cocrystal Pharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revolution Medicines | $11.58 million | 3,474.12 | -$1.13 billion | ($7.07) | -26.77 |
| Cocrystal Pharma | N/A | N/A | -$8.83 million | ($0.73) | -1.23 |
Analyst Ratings
This is a summary of recent ratings and price targets for Revolution Medicines and Cocrystal Pharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revolution Medicines | 1 | 1 | 18 | 2 | 2.95 |
| Cocrystal Pharma | 1 | 0 | 0 | 0 | 1.00 |
Revolution Medicines currently has a consensus target price of $144.67, suggesting a potential downside of 23.55%. Given Revolution Medicines’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Revolution Medicines is more favorable than Cocrystal Pharma.
Profitability
This table compares Revolution Medicines and Cocrystal Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revolution Medicines | N/A | -83.22% | -59.06% |
| Cocrystal Pharma | N/A | -150.61% | -97.86% |
Institutional and Insider Ownership
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Revolution Medicines has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.
Summary
Revolution Medicines beats Cocrystal Pharma on 8 of the 13 factors compared between the two stocks.
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
About Cocrystal Pharma
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
